Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia

Last updated: July 24, 2017
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Active - Recruiting

Phase

3

Condition

Thrombosis

Platelet Disorders

Leukemia (Pediatric)

Treatment

N/A

Clinical Study ID

NCT02611973
P140933
  • Ages > 18
  • All Genders

Study Summary

The hypothesis is that efficient prevention of thrombosis with aspirin at diagnosis becomes less useful once patients have achieved a hematologic response (HR) (modified by amendment 1/03/2017) and/or that this benefit is hampered by an increased hemorrhagic risk especially in elderly patients.

Hence, investigator propose a prospective randomized study to assess the benefit / risk ratio of aspirin maintenance in high risk Essential thrombocythemia (ET) patients, in hematological response (modified by amendment 1/03/2017) on Hydroxyurea.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • > 18 years and older (modified by amendment 01/03/2017)

  • Contraception considered effective by the investigator: for women of childbearing andfor men whose partner is likely to procreate (added by amendment 01/03/2017)

  • Diagnosis of ET performed within the last 10 years (modified by amendment 01/03/2017) : with or without Janus kinase 2V617F (JAK2V617F) mutation accordingto the WHO 2008 criteria (TEFFERI,2007)

  • ET patients currently treated with hydroxyurea in first line, who have achieved acomplete or partial hematologic response according to the ELN 2009 (BAROSI, 2009)modified (at least three month apart and at inclusion) (modified by amendment 01/03/2017)

  • Signed Written Informed Consent

  • Health insurance coverage.

Exclusion

Exclusion Criteria:

  • Other myeloproliferative disorder than ET.

  • Contra-indication to hydroxyurea.

  • Other uncontrolled malignancies at the time of diagnosis or inclusion.

  • History of haemostasis perturbation not related to ET, associated with a significantrisk of hemorrhage or thrombosis (modified by amendment 01/03/2017)

-.• Pregnancy or breastfeeding (added by amendment 01/03/2017)

  • Inability to freely provide consent through judiciary or administrative condition.

Study Design

Total Participants: 2250
Study Start date:
March 10, 2016
Estimated Completion Date:
November 30, 2022

Study Description

ET is a myeloproliferative neoplasm (MPN) characterized by a high platelet level. Increased occurrence of thrombosis and hemorrhages are the main complications in ET. In this regard, the key factors defining high risk ET include age over 60 years, past history of thrombosis, platelet > 1500 109/L and to a lesser degree cardiovascular risk factors. These criteria currently serve as therapeutic guidelines for the use of cytoreductive therapy, with hydroxyurea (HU) being the treatment of choice in the first line setting.

The use of antiplatelet agent i.e. low-dose aspirin is also generally recommended. However, the benefit of aspirin has never been formally demonstrated in ET. Only indirect evidence come from the ECLAP study that enrolled patients with polycythemia vera (PV). Of note in the ECLAP study, the efficacy of aspirin was assessed only at diagnosis but not correlated thereafter with the hematological response on cytoreductive therapy.

In general non-MPN population studies, primary prophylaxis with aspirin has been associated with a risk reduction of major vascular events, but an increased risk of hemorrhage, especially considering age and prior gastrointestinal history. In a recent retrospective study, the combination of aspirin and cytoreduction was reported to prevent thrombosis but concomitantly increase the bleeding risk when compared to HU alone , especially in patients older than 60 years, thus questioning the benefits of long term use of aspirin therapy. These data raise the question of the actual benefit of aspirin maintenance, once patients have been efficiently treated with cytoreductive therapy.

Hence, investigator propose a prospective randomized study to assess the benefit / risk ratio of aspirin maintenance in high risk ET patients, in hematological response (modified by amendment 1/03/2017) on Hydroxyurea. Patients for which Aspirin interruption will not be possible because of extra-ET indications will be enrolled in the control observational arm.

Connect with a study center

  • Henri Mondor Hospital

    Creteil, 94010
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.